Quantum Biopharma Ltd. (NASDAQ:QNTM) Short Interest Up 41.4% in February

Quantum Biopharma Ltd. (NASDAQ:QNTM) saw a significant growth in short interest in February. As of February 13th, there was short interest totaling 108,439 shares, a growth of 41.4% from the January 29th total of 76,665 shares. Based on an average daily trading volume, of 74,262 shares, the days-to-cover ratio is currently 1.5 days. Currently, 3.1% of the company’s shares are sold short. Currently, 3.1% of the company’s shares are sold short. Based on an average daily trading volume, of 74,262 shares, the days-to-cover ratio is currently 1.5 days.

Quantum Biopharma Trading Up 1.4%

NASDAQ:QNTM traded up $0.05 on Monday, hitting $3.60. 45,488 shares of the company’s stock traded hands, compared to its average volume of 53,794. The company has a market cap of $13.75 million, a PE ratio of -0.33 and a beta of 0.33. Quantum Biopharma has a 1 year low of $3.41 and a 1 year high of $38.25. The firm has a 50-day moving average price of $5.61 and a 200-day moving average price of $10.59.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Quantum Biopharma in a research report on Monday, December 29th. Wall Street Zen lowered shares of Quantum Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, January 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Quantum Biopharma has an average rating of “Sell”.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new stake in shares of Quantum Biopharma during the 4th quarter valued at $80,000. Virtu Financial LLC acquired a new position in shares of Quantum Biopharma in the fourth quarter worth $76,000. Finally, Steward Partners Investment Advisory LLC acquired a new position in shares of Quantum Biopharma in the second quarter worth $63,000. Institutional investors and hedge funds own 1.24% of the company’s stock.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.